tiprankstipranks
Trending News
More News >
Draegerwerk AG & Co. KGaA (DE:DRW3)
:DRW3
Advertisement

Draegerwerk AG & Co. KGaA (DRW3) AI Stock Analysis

Compare
9 Followers

Top Page

DE:DRW3

Draegerwerk AG & Co. KGaA

(LSE:DRW3)

Rating:66Neutral
Price Target:
€74.00
▲(11.78% Upside)
Draegerwerk AG & Co. KGaA's overall stock score is driven by a stable financial position with some challenges in revenue and cash flow. The technical analysis suggests cautious sentiment, while the valuation indicates potential undervaluation with a decent dividend yield. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Financial Performance
Despite strong order intake and a favorable product mix supporting performance, the EBIT estimates are raised by 5-7%.
Order Intake
Preliminary calculated order intake was 10.5% above the level of the prior-year period, showing strong demand.
Negative Factors
Profitability
EBIT came in significantly lower at €20m compared to the previous year's €40.7m, reflecting reduced profitability.
Revenue
Q2 net sales decreased by 0.6% from the prior-year period, indicating a decline in revenue.

Draegerwerk AG & Co. KGaA (DRW3) vs. iShares MSCI Germany ETF (EWG)

Draegerwerk AG & Co. KGaA Business Overview & Revenue Model

Company DescriptionDrägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as fire training facilities for firefighters. Drägerwerk AG & Co. KGaA was founded in 1889 and is headquartered in Lübeck, Germany.
How the Company Makes MoneyDraegerwerk generates revenue through the sale of its medical and safety products, which are distributed globally to hospitals, healthcare institutions, and industrial companies. Key revenue streams include direct sales of medical devices and safety equipment, service contracts for maintenance and support, and consumables associated with their products. The company also benefits from partnerships with healthcare providers and governmental agencies that bolster its market presence and facilitate access to new clients. Additionally, Draegerwerk invests in research and development to innovate and expand its product offerings, which helps maintain a competitive edge and drives future earnings.

Draegerwerk AG & Co. KGaA Financial Statement Overview

Summary
Draegerwerk AG & Co. KGaA presents a robust financial profile with solid profitability and a strong equity base. The company manages its leverage well, maintaining a healthy balance between debt and equity. However, it faces challenges in revenue growth and free cash flow expansion. Strategic improvements in revenue streams and operational efficiency could enhance financial performance further.
Income Statement
72
Positive
Draegerwerk AG & Co. KGaA shows a stable revenue base with a slight decline in recent years. The gross profit margin remains strong at approximately 44.9% in 2024, reflecting effective cost management. The net profit margin improved to 3.7% in 2024 from 3.3% in 2023, indicating better profitability despite revenue stagnation. However, the EBIT margin decreased slightly from 5.5% in 2023 to 5.3% in 2024, suggesting some operational challenges. Overall, the company exhibits solid profitability but faces challenges in revenue growth.
Balance Sheet
68
Positive
The balance sheet reveals a reasonable debt-to-equity ratio of 0.26 in 2024, indicating conservative leverage. The company has improved its equity ratio to 49.6%, showcasing a solid equity base relative to its assets. Return on equity (ROE) stands at 8.1%, reflecting moderate efficiency in using equity to generate profit. While leverage is manageable, the company should focus on enhancing asset utilization to boost returns.
Cash Flow
75
Positive
In 2024, Draegerwerk AG & Co. KGaA demonstrated a positive free cash flow of €103.5 million, although it decreased from €121.5 million in 2023. The operating cash flow to net income ratio of 1.34 indicates strong cash generation relative to net earnings. However, the free cash flow growth rate was negative, highlighting a need for sustained cash flow improvement. Overall, the company maintains healthy cash generation but faces challenges in improving free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.36B3.37B3.37B3.05B3.33B3.41B
Gross Profit1.51B1.51B1.46B1.24B1.54B1.61B
EBITDA315.73M351.68M318.33M62.63M374.43M399.92M
Net Income99.86M124.41M110.43M-64.56M154.23M188.59M
Balance Sheet
Total Assets2.99B3.09B3.09B3.11B3.18B3.31B
Cash, Cash Equivalents and Short-Term Investments218.91M248.18M279.36M319.50M577.38M650.56M
Total Debt446.92M395.58M471.38M361.95M348.01M370.75M
Total Liabilities1.52B1.56B1.69B1.79B1.92B2.27B
Stockholders Equity1.46B1.54B1.41B1.32B1.26B1.03B
Cash Flow
Free Cash Flow122.22M103.52M121.47M-231.09M274.54M345.04M
Operating Cash Flow190.64M167.31M189.68M-144.23M384.89M459.98M
Investing Cash Flow-92.53M-43.39M-67.34M36.83M-109.92M-263.08M
Financing Cash Flow-103.70M-161.38M-154.56M-29.38M-334.64M114.25M

Draegerwerk AG & Co. KGaA Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price66.20
Price Trends
50DMA
68.02
Negative
100DMA
65.80
Positive
200DMA
58.35
Positive
Market Momentum
MACD
-0.05
Positive
RSI
40.07
Neutral
STOCH
34.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW3, the sentiment is Neutral. The current price of 66.2 is below the 20-day moving average (MA) of 67.92, below the 50-day MA of 68.02, and above the 200-day MA of 58.35, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.07 is Neutral, neither overbought nor oversold. The STOCH value of 34.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:DRW3.

Draegerwerk AG & Co. KGaA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
€1.13B12.436.87%3.07%-0.03%-14.15%
51
Neutral
$7.85B-0.21-41.41%2.22%22.81%-2.01%
€3.85B24.347.48%
€1.26B67.692.87%
€1.07B-16.75%
€12.85B19.574.83%
$61.73B26.2311.75%1.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:DRW3
Draegerwerk AG & Co. KGaA
66.20
22.29
50.75%
GB:0DHC
Carl Zeiss Meditec
43.10
-20.54
-32.28%
GB:0MSD
CompuGroup Medical
23.88
8.71
57.42%
GB:0IRF
Evotec
5.99
-0.55
-8.41%
GB:0H9X
Fresenius Medical Care AG & Co. KGaA
43.79
10.04
29.75%
SEMHF
Siemens Healthineers AG
55.32
-1.50
-2.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025